looks good

https://www.malaysianewslab.com/zh/news_cn/20210625-6/

永大集团首席执行员拿督威拉巫光伦指出，在面对新冠肺炎疫情持续严峻的情况下，向来以发展房地产及旅游文化产业为主轴的永大集团，必需开发其他领域，以便寻找可以为集团带来收入的投资与发展。

因此，他说，该集团在今年先后进军开採金矿、数码资产交易平台及最近的生物医药领域，引进研发疫苗技术，并希望在疫情期间，可以为集团带来盈利。

他是在与乐天交易（Rakuten Trade）进行的线上座谈会上，发表上述谈话；共有逾百人参与这项线上座谈会，并且进行了长达1 小时。

some comment from volunteer

https://www.malaysianewslab.com/zh/news_cn/20210625-7/

随着永大集团日前宣布跨界到进入门槛颇高的生物医药领域、把新研发疫苗引入大马，成为我国首家获政府批准在国内进行深圳康泰疫苗第三期试验的私人企业，该项针对冠病灭活疫苗三期临床实验已正式开始。
其中一名自愿者How Ching Ching （面子书帐名）在面书发文，难掩其兴奋的心情。

3 months ago -->
Prg Holdings Posts Quarterly Revenue 35.7 Million RGT Versus 56.7 Million RGT

KNM Group Bhd has proposed a private placement of up to 987.52 million new shares, representing 30% of its share capital, to raise RM167.9 million in proceeds for the purpose of repaying its bank borrowings.

The engineering group said up to 493.75 million or 50% of the placement shares will be placed out to its executive vice chairman and major shareholder, Gan Siew Liat.

https://www.theedgemarkets.com/article/knm-proposes-private-placement-raise-rm168m-repay-borrowings

lets prepare pop corn

IN a week, Serba Dinamik Holdings Bhd has lost more than RM3 billion, or half of its market value, resulting in many market watchers saying that the company’s stellar run has come to an end.

While company officials, especially managing director and CEO Datuk Mohd Abdul Karim Abdullah (pictured), have said time and again that there is nothing untoward at Serba Dinamik, auditors KPMG’s queries regarding more than RM4.54 billion worth of transactions at the company have unsettled investors. Since the disclosure of the red flags raised over these transactions, Serba Dinamik’s stock has plunged more than 52%, over the week to close at 76.5 sen last Friday.

agreed with you bro

https://www.reuters.com/article/us-health-coronavirus-vaccine-kangtai-idUSKBN2CV1F6


Kangtai Biological's COVID-19 vaccine gets emergency use approval in China
By Reuters Staff


BEIJING (Reuters) - China has given emergency use approval to a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products, the company said on Friday, adding a sixth shot to the country’s vaccination drive.

China has already administered 366.9 million doses to people using five home-made products, three of which adopt a similar technology as the Kangtai shot, where inactivated coronavirus that cannot replicate in human cells is used to trigger an immune response.

Kangtai did not say on Friday what sectors of China’s population its shot could be used in, when use would start or how long the approval will be effective.

A clinical trial record in April said Kangtai aimed to start a Phase III clinical trial this month involving 28,000 participants aged 18 and above to evaluate the efficacy and safety of its two dose-based shot given 28 days apart.

The record, published in the site ClinicalTrials.gov, which is maintained by a department under the National Institute of Health of the United States, did not specify where the trial will take place.

China’s vaccine administration law allows emergency use “within certain scope and time limit” of vaccines during major health crises. A COVID-19 shot from a unit of Chongqing Zhifei Biological Products is also being used in the country under emergency clearance.

Kangtai has also obtained exclusive right to develop and manufacture the vaccine developed by AstraZeneca and Oxford University in mainland China.

Reporting by Roxanne Liu and Meg Shen; Editing by Frances Kerry

Fintech is the future. Good move.